Gross Motor Development by Age and Functional Level in Children with Cerebral Palsy from 6 Months to 17 Years-A

Reidun Birgitta Jahnsen1,2, Harald Weedon-Fekjar3, Gerd Myklebust1

  • 1Norwegian Quality and Surveillance Registry of Cerebral Palsy, Oslo University Hospital, 0424 Oslo, Norway.

PubMed

Insights

Norwegian children with cerebral palsy show motor development similar to Canadian peers. The Gross Motor Function Measure (GMFM-66) reference curves are valid for both populations, with Norwegian data available from an earlier age.

Area of Science:

  • Pediatrics
  • Neurology
  • Rehabilitation Medicine

Background:

  • Cerebral palsy (CP) is a complex, lifelong disability resulting from immature brain injury.
  • Assessing interventions for children with CP necessitates validated and reliable outcome measures.
  • Motor development curves and reference percentiles, such as those from the Gross Motor Function Measure (GMFM-66), are crucial for tracking and evaluating gross motor skill changes.

Purpose of the Study:

  • To establish motor development curves and reference percentiles using Norwegian data for children aged 2-21 years.
  • To compare these Norwegian curves with existing Canadian reference data.
  • To assess the applicability of current GMFM-66 reference curves in a Norwegian context.

Main Methods:

  • Utilized prospective, population-based cohort data from the Norwegian Quality and Surveillance Registry for Cerebral Palsy (NorCP).
  • Included 1206 children with 3612 GMFM-66 tests administered between 0.5 and 17.3 years of age.
  • Employed generalized additive regression models (GAMLSS) to estimate median development by Gross Motor Function Classification System (GMFCS) levels, adjusting for repeated measurements.

Main Results:

  • Norwegian motor development curves for GMFCS levels I-IV show an increase up to age 7, followed by a plateau.
  • GMFCS level V curves in Norway remain relatively flat.
  • Both the Norwegian motor development curves and GMFM-66 percentiles closely resemble their Canadian counterparts.

Conclusions:

  • The established Canadian reference curves for GMFM-66 are applicable and valid for use in Norway.
  • These curves are suitable for both clinical practice and research purposes in Norway.
  • Norwegian reference percentiles derived from this study can be utilized from an earlier age compared to existing Canadian data.